Abstract
The main pathogen in the oral cavity is of bacteriological origin; virus and fungal infection also account for oral malady as primary or secondary site. Thus, drug delivery to the oral cavity should be diversified, as the pathogens and pathogenicity have many faces and modes of action. In this chapter, various pathogens and numerous drug delivery systems are presented, and a growing trend in drug delivery to the oral cavity has been emphasized. Oral manifestations of systemic viral disease are common and represent an everlasting challenge to physicians. Fungal infections are also found in the oral cavity, usually as opportunistic infections secondary to a debilitating systemic condition. The harsh conditions of the oral environment are often a cause for micro- or macro-trauma to the soft and hard tissues of the oral cavity and present a challenge to drug treatment. If the drug is designated to act locally in the oral cavity and to remain in the site for a measured period of time, the dynamic conditions in the mouth such as changing pH levels, masticatory abrasion, slippery mucosa, and smooth teeth surfaces must all be taken into consideration for adhering a delivering tool. Polymers are one answer to the harsh demands of the oral cavity, as they can supply both a delivery tool and sustained-release apparatus, for example, use of polymeric microspheres; in general, microspheres have the potential to be used for targeted and controlled-release drug delivery. However, coupling of mucoadhesive properties to microspheres has additional advantages like more intimate contact with the mucus layer, efficient absorption, and enhanced bioavailability of the drugs due to a high surface-to-volume ratio.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Takahashi N (2005) Microbial ecosystem in the oral cavity: metabolic diversity in an ecological niche and its relationship with oral diseases. Int Congr Ser 1284:103–112
Sudhakar Y, Kuotsu K, Bandyopadhyay AK (2006) Buccal bioadhesive drug delivery–a promising option for orally less efficient drugs. J Control Release 114(1):15–40
Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH (2012) New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 64(1):16–28
Dixit RP, Puthli SP (2009) Oral strip technology: overview and future potential. J Control Release 139(2):94–107
Roy S, Prabhakar B (2010) Bioadhesive polymeric platforms for transmucosal drug delivery systems—a review. Trop J Pharm Res 9(1):91–104
Heasman PA, Heasman L, Stacey F, McCracken GI (2001) Local delivery of chlorhexidine gluconate (PerioChip) in periodontal maintenance patients. J Clin Periodontol 28(1):90–95
Soskolne WA, Chajek T, Flashner M, Landau I, Stabholtz A, Kolatch B, Lerner EI (1998) An in vivo study of the chlorhexidine release profile of the PerioChip in the gingival crevicular fluid, plasma and urine. J Clin Periodontol 25(12):1017–1021
Stabholz A, Shapira L, Mahler D, Gellman Y, Ramon T, Dolev E, Schwartz M, Berger L, Proskin HM, Finkelman RD, Flashner M, Kolatch B, Soskolne A (2000) Using the PerioChip in treating adult periodontitis: an interim report. Compend Contin Educ Dent 21(4):325–328, 330, 332 passim; quiz 338
Dreizen S, Keating MJ, Beran M (1992) Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. Postgrad Med 91(5):349–350, 353–344, 357–360 passim
Kovacs SO, Hruza LL (1995) Superficial fungal infections. Getting rid of lesions that don’t want to go away. Postgrad Med 98(6):61–62, 68–69, 73–75
Carpenter W, Schiff T, Fat D (1997) Adherence of two film-forming medications to the oral mucosa. Gen Dent 45(5):478–480
Redding SW, Haveman CW (1999) Treating the discomfort of oral ulceration resulting from cancer chemotherapy. Compend Contin Educ Dent 20(4):389–392, 394, 396
Lindquist B, Gisselsson H, Wennerholm K (2010) Effect of chlorhexidine gel on approximal caries increment in adolescents with high caries risk using professional flossing compared to individual trays. Swed Dent J 34(1):17–25
Unsal E, Akkaya M, Walsh TF (1994) Influence of a single application of subgingival chlorhexidine gel or tetracycline paste on the clinical parameters of adult periodontitis patients. J Clin Periodontol 21(5):351–355
Wallman C, Birkhed D (2002) Effect of chlorhexidine varnish and gel on mutans streptococci in margins of restorations in adults. Caries Res 36(5):360–365
Bonito AJ, Lux L, Lohr KN (2005) Impact of local adjuncts to scaling and root planing in periodontal disease therapy: a systematic review. J Periodontol 76(8):1227–1236
Eberhard J, Jepsen S, Jervoe-Storm PM, Needleman I, Worthington HV (2008) Full-mouth disinfection for the treatment of adult chronic periodontitis. Cochrane Database Syst Rev (1):CD004622
Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S (2002) A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol 29(Suppl 3):136–159, discussion 160-132
Jeffcoat MK, Bray KS, Ciancio SG, Dentino AR, Fine DH, Gordon JM, Gunsolley JC, Killoy WJ, Lowenguth RA, Magnusson NI, Offenbacher S, Palcanis KG, Proskin HM, Finkelman RD, Flashner M (1998) Adjunctive use of a subgingival controlled-release chlorhexidine chip reduces probing depth and improves attachment level compared with scaling and root planing alone. J Periodontol 69(9):989–997
Schwach-Abdellaoui K, Vivien-Castioni N, Gurny R (2000) Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur J Pharm Biopharm 50(1):83–99
Baer PN (1995) Actisite (tetracycline hydrochloride periodontal fiber) not a product for the pediatric dentist. J Clin Pediatr Dent 19(2):147
Litch JM, Encarnacion M, Chen S, Leonard J, Burkoth TL (1996) Use of the polymeric matrix as internal standard for quantitation of in vivo delivery of tetracycline HCl from Actisite tetracycline fiber during periodontal treatment. J Periodontal Res 31(8):540–544
Dodwad V, Ahuja S, Kukreja BJ (2012) Effect of locally delivered tetracycline hydrochloride as an adjunct to scaling and root planing on Hba1c, C-reactive protein, and lipid profile in type 2 diabetes: a clinico-biochemical study. Contemp Clin Dent 3(2):150–154
Ciancio SG (1999) Local delivery of chlorhexidine. Compend Contin Educ Dent 20(5):427–432, quiz 434
Killoy WJ (1998) The use of locally delivered chlorhexidine in the treatment of periodontitis. Clinical results. J Clin Periodontol 25(11 Pt 2):953–958, discussion 978-959
Grover V, Kapoor A, Malhotra R, Battu VS, Bhatia A, Sachdeva S (2011) To assess the effectiveness of a chlorhexidine chip in the treatment of chronic periodontitis: a clinical and radiographic study. J Indian Soc Periodontol 15(2):139–146
Kondreddy K, Ambalavanan N, Ramakrishna T, Kumar RS (2013) Effectiveness of a controlled release chlorhexidine chip (PerioCol-CG) as an adjunctive to scaling and root planing when compared to scaling and root planing alone in the treatment of chronic periodontitis: a comparative study. J Indian Soc Periodontol 16(4):553–557
Chandra C, Valavalkar N, Vandana KL (2011) The comparative evaluation of xanthan gel with chlorhexidine (Chlosite) in smokers and non-smokers: a clinical and microbiological assessment. J Indian Soc Periodontol 15(3):221–227
Zeidner NS, Massung RF, Dolan MC, Dadey E, Gabitzsch E, Dietrich G, Levin ML (2008) A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite. J Med Microbiol 57(Pt 4):463–468
(1994) Antibiotic gels for periodontal disease. Drug Ther Bull 32(6):43–44
Jarrold CR, Allaker RP, Young KA, Heath MR, Hardie JM, Lynch E (1997) Clinical and microbiological effects of topical minocycline in the treatment of elderly patients with periodontitis. Br Dent J 183(2):51–56
Kinane DF (2000) Local antimicrobial therapies in periodontal disease. Ann R Australas Coll Dent Surg 15:57–60
Geng S, Cao C, Chen Z (2000) The effect of non-surgical periodontal and adjunctive minocycline-HCL treatments on collagenase activity. Zhonghua Kou Qiang Yi Xue Za Zhi 35(5):336–339
Hagiwara S, Iida M, Ishikawa I (1993) Clinical and microbiological study concerning effects of scaling and root planing. 2. The effects of mechanical debridement until one year and of minocycline application topically. Kokubyo Gakkai Zasshi 60(2):301–312
Hagiwara S, Umeda M, Tominaga Y, Takamatsu N, Yoshida N (1995) Subgingival distribution of periodontopathic bacteria in periodontic patients and susceptibility of these bacteria to minocycline-HCl. Kokubyo Gakkai Zasshi 62(4):495–505
Nakagawa T, Yamada S, Oosuka Y, Saito A, Hosaka Y, Ishikawa T, Okuda K (1991) Clinical and microbiological study of local minocycline delivery (Periocline) following scaling and root planing in recurrent periodontal pockets. Bull Tokyo Dent Coll 32(2):63–70
Lessem J, Hanlon A (2004) A post-marketing study of 2805 patients treated for periodontal disease with Arestin. J Int Acad Periodontol 6(4 Suppl):150–153
Oringer RJ, Van Dyke TE, Lessem J (2002) The challenge of treating periodontal patients who smoke–the efficacy of Arestin. J Int Acad Periodontol 4(3):89–94
Skaleric U, Schara R, Medvescek M, Hanlon A, Doherty F, Lessem J (2004) Periodontal treatment by Arestin and its effects on glycemic control in type 1 diabetes patients. J Int Acad Periodontol 6(4 Suppl):160–165
Van Dyke TE, Offenbacher S, Braswell L, Lessem J (2002) Enhancing the value of scaling and root-planing: Arestin clinical trial results. J Int Acad Periodontol 4(3):72–76
Al-Mubarak SA, Karring T, Ho A (2000) Clinical evaluation of subgingival application of metronidazole 25%, and adjunctive therapy. J Int Acad Periodontol 2(3):64–70
Montebugnoli L, Servidio D, Prati C (2002) Effectiveness of metronidazole gel on cyclosporine-induced gingival overgrowth in heart transplant patients. Clin Oral Investig 6(1):24–27
Candio S Actisite® (tetracycline hydrochloride) and the recare patient. Dentistry IQ, Tulsa, OK
PerioCol-TC Sterile medicated periodontal collagen fibers. Eucare Pharmaceuticals, India
Dodwad V, Vaish S, Mahajan A, Chhokra M (2012) Local drug delivery in periodontics: a strategic intervention. Int J Pharm Pharm Sci 4(4):30–34
PerioChip Dexcel Pharma Technologies, Fair Lawn, NJ
Arestin Minocycline microspheres. OraPharma, Inc., Horsham, PA
Jain R, Mohamed F, Hemalatha M (2012) Minocycline containing local drug delivery system in the management of chronic periodontitis: a randomized controlled trial. J Indian Soc Periodontol 16(2):179–183
Salamat-Miller N, Chittchang M, Johnston TP (2005) The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 57(11):1666–1691
Shinkar DM, Dhake AS, Setty CM (2012) Drug delivery from the oral cavity: a focus on mucoadhesive buccal drug delivery systems. PDA J Pharm Sci Technol 66(5):466–500
Segal AL, Katcher AH, Brightman VJ, Miller MF (1974) Recurrent herpes labialis, recurrent aphthous ulcers, and the menstrual cycle. J Dent Res 53(4):797–803
Gaffar A (2001) Recurrent oral ulcers—an overview. Compend Contin Educ Dent Suppl (32):4–6. quiz 22
Reznik D, O’Daniels CM (2001) Clinical treatment evaluations of a new topical oral medication. Compend Contin Educ Dent Suppl (32):17–21, quiz 23
Mizrahi B, Golenser J, Wolnerman JS, Domb AJ (2004) Adhesive tablet effective for treating canker sores in humans. J Pharm Sci 93(12):2927–2935
Pica F, Volpi A (2011) Public awareness and knowledge of herpes labialis. J Med Virol 84(1):132–137
Raborn GW, McGaw WT, Grace M, Percy J (1988) Treatment of herpes labialis with acyclovir. Review of three clinical trials. Am J Med 85(2A):39–42
Spruance SL (2002) N-docosanol (Abreva) for herpes labialis: problems and questions. J Am Acad Dermatol 47(3):457–458
Quong TL (1989) Oral acyclovir (Zovirax) in the treatment of recurrent herpetic gingivostomatitis and recurrent herpes labialis. Hawaii Dent J 20(10):10, 12, 14 passim
Poland JM (1994) Current therapeutic management of recurrent herpes labialis. Gen Dent 42(1):46–50, quiz 51-42
Raborn GW, Chan KS, Grace M (2004) Treatment modalities and medication recommended by health care professionals for treating recurrent herpes labialis. J Am Dent Assoc 135(1):48–54
Raborn GW, Grace MG (2003) Recurrent herpes simplex labialis: selected therapeutic options. J Can Dent Assoc 69(8):498–503
McCarthy JP, Browning WD, Teerlink C, Veit G (2012) Treatment of herpes labialis: comparison of two OTC drugs and untreated controls. J Esthet Restor Dent 24(2):103–109
Berry TM, Murphy JA, Montooth AK, Hing E, Cherry DK, Woodwell DA National Ambulatory Medical Care Survey: 2003 summary. Accessed at http://0-www.cdc.gov.mill1.sjlibrary.org/nchs/data/ad/ad365.pdf 9 Feb 2007
Pearson NL (2006) Product update. Can Pharm J/Revue des Pharmaciens du Canada 139(5):1–4
ORAJEL™ Single Dose Cold Sore Treatment http://www.orajel.com/adult-oral-care/cold-sore/Products/orajel-single-dose-cold-sore-treatment.aspx
Sterer N, Nuas S, Mizrahi B, Goldenberg C, Weiss EI, Domb A, Davidi MP (2008) Oral malodor reduction by a palatal mucoadhesive tablet containing herbal formulation. J Dent 36(7):535–539
Sterer N, Rubinstein Y (2006) Effect of various natural medicinals on salivary protein putrefaction and malodor production. Quintessence Int 37(8):653–658
Danser MM, Gomez SM, Van der Weijden GA (2003) Tongue coating and tongue brushing: a literature review. Int J Dent Hyg 1(3):151–158
Pedrazzi V, Sato S, de Mattos Mda G, Lara EH, Panzeri H (2004) Tongue-cleaning methods: a comparative clinical trial employing a toothbrush and a tongue scraper. J Periodontol 75(7):1009–1012
Quirynen M, Avontroodt P, Soers C, Zhao H, Pauwels M, van Steenberghe D (2004) Impact of tongue cleansers on microbial load and taste. J Clin Periodontol 31(7):506–510
Lourith N, Kanlayavattanakul M (2010) Oral malodour and active ingredients for treatment. Int J Cosmet Sci 32(5):321–329
Meyers AJ, Lutrario CA, Elliott M, Gallagher LA Breath freshening lipstick. US Patent 63834752002
Pankhurst CL (2012) Candidiasis (oropharyngeal). Clin Evid (Online) 2012:pii: 1304
Pienaar ED, Young T, Holmes H (2006) Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev (3):CD003940
Klotz SA (2006) Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 42(8):1187–1188
(2010) Miconazole (Oravig) for oropharyngeal candidiasis. Med Lett Drugs Ther 52(1352):95–96
Lalla RV, Bensadoun RJ (2010) Miconazole mucoadhesive tablet for oropharyngeal candidiasis. Expert Rev Anti Infect Ther 9(1):13–17
Collins CD, Cookinham S, Smith J (2011) Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. Patient Prefer Adherence 5:369–374
Tibozole. http://preprod.www.tibotec.com/bgdisplay.jhtml?itemname=products_characteristics
Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E (2004) Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 35(2):144–150
Bensadoun RJ, Daoud J, El Gueddari B, Bastit L, Gourmet R, Rosikon A, Allavena C, Ceruse P, Calais G, Attali P (2008) Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 112(1):204–211
Resorba repair and regenerate Vol. 2013
Orellana MF, Lagravere MO, Boychuk DG, Major PW, Flores-Mir C (2006) Prevalence of xerostomia in population-based samples: a systematic review. J Public Health Dent 66(2):152–158
Napenas JJ, Brennan MT, Fox PC (2009) Diagnosis and treatment of xerostomia (dry mouth). Odontology 97(2):76–83
Rayman S, Dincer E, Almas K (2010) Xerostomia. Diagnosis and management in dental practice. N Y State Dent J 76(2):24–27
Dodds MW, Hsieh SC, Johnson DA (1991) The effect of increased mastication by daily gum-chewing on salivary gland output and dental plaque acidogenicity. J Dent Res 70(12):1474–1478
Jenkins GN, Edgar WM (1989) The effect of daily gum-chewing on salivary flow rates in man. J Dent Res 68(5):786–790
Odusola F (1991) Chewing gum as aid in treatment of hyposalivation. N Y State Dent J 57(4):28–31
Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35(2):132–137
Yankell SL, Emling RC (1989) Clinical study to evaluate the effects of three marketed sugarless chewing gum products on plaque pH, pCa, and swallowing rates. J Clin Dent 1(3):70–74
Rhodus NL, Bereuter J (2000) Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjogren’s syndrome. J Otolaryngol 29(1):28–34
Lafaurie G, Fedele S, Lopez RM, Wolff A, Strietzel F, Porter SR, Konttinen YT (2009) Biotechnological advances in neuro-electro-stimulation for the treatment of hyposalivation and xerostomia. Med Oral Patol Oral Cir Bucal 14(2):E76–E80
Pattani KM, McDuffie CM, Morgan M, Armstrong C, Nathan CO (2010) Electrical stimulation of post-irradiated head and neck squamous cell carcinoma to improve xerostomia. J La State Med Soc 162(1):21–25
Braga MA, Tarzia O, Bergamaschi CC, Santos FA, Andrade ED, Groppo FC (2009) Comparison of the effects of pilocarpine and cevimeline on salivary flow. Int J Dent Hyg 7(2):126–130
al-Hashimi I, Taylor SE (2001) A new medication for treatment of dry mouth in Sjogren’s syndrome. Tex Dent J 118(3):262–266
Walizer EM, Ephraim PM (1996) Double-blind cross-over controlled clinical trial of vegetable oil versus xerolube for xerostomia: an expanded study abstract. ORL Head Neck Nurs 14(1):11–12
Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14(4):319–326
Devlin H, Bassiouny MA, Boston D (2006) Hardness of enamel exposed to Coca-Cola and artificial saliva. J Oral Rehabil 33(1):26–30
Nieuw Amerongen AV, Veerman EC (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11(4):226–231
Shannon IL, Trodahl JN, Starcke EN (1978) Remineralization of enamel by a saliva substitute designed for use by irradiated patients. Cancer 41(5):1746–1750
Meyer-Lueckel H, Schulte-Monting J, Kielbassa AM (2002) The effect of commercially available saliva substitutes on predemineralized bovine dentin in vitro. Oral Dis 8(4):192–198
Schaeken MJ, van der Hoeven JS (1990) Plax more effective than water? Ned Tijdschr Tandheelkd 97(7):315–317
Guneri P, Alpoz E, Epstein JB, Cankaya H, Ates M (2011) In vitro antimicrobial effects of commercially available mouth-wetting agents. Spec Care Dentist 31(4):123–128
Kerr AR, Corby PM, Shah SS, Epler M, Fisch GS, Norman RG (2010) Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc 141(10):1250–1256
Senahayake F, Piggott K, Hamilton-Miller JM (1998) A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin 14(3):155–159
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Controlled Release Society
About this chapter
Cite this chapter
Qureshi, S., Khan, W., Perez-Davidi, M., Weiss, E.I., Beyth, N., Domb, A.J. (2014). Local Drug Delivery to the Oral Cavity. In: Domb, A., Khan, W. (eds) Focal Controlled Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9434-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9434-8_13
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-9433-1
Online ISBN: 978-1-4614-9434-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)